Michael Launspach

CRISPR-dPCR quantifies CRISPR knock-in by distinguishing integration from donor abundance and background, using multiplex digital PCR with orthogonal strategies.

This paper develops a lipid nanoparticle (LNP) platform for non-viral CRISPR-mediated homology directed repair (HDR) to generate CAR T cells with improved efficiency and reduced toxicity compared to electroporation.

This paper develops a non-viral CRISPR/Cas9 HDR platform for stable transgene knock-in in solid tumor models, achieving up to 60% efficiency in neuroblastoma cells.

This study shows that unmodified mRNA can be used for CAR-T cell engineering without compromising function, eliminating the need for costly nucleoside modifications.

This paper develops CancerPAM, a bioinformatics pipeline for identifying CRISPR knock-in sites to remodel the tumor microenvironment, enhancing CAR T cell therapy in solid tumors.